Barclays Upgrades Ionis Pharmaceuticals (IONS) to Equalweight

Barclays analyst Gena Wang upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Underweight to Equalweight with a price target of $52.00 (from $50.00).

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $52.40 yesterday.

You May Also Be Interested In

• UPDATE: UBS Upgrades EnLink Midstream, LLC (ENLC) to Buy
• UPDATE: Benchmark Upgrades AutoNation Inc. (AN) to Buy
• UPDATE: Stephens Upgrades Webster Financial (WBS) to Overweight